uracil has been researched along with Kidney Diseases in 7 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The direct-acting antiviral agent (DAA) combination of ombitasvir and paritaprevir (administered with ritonavir) with (3D regimen) or without (2D regimen) dasabuvir has shown very high efficacy rates in the treatment of chronic hepatitis C virus (HCV) infection." | 5.24 | Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment. ( Awni, WM; Dutta, S; Khatri, A; Marbury, TC; Menon, RM; Preston, RA; Rodrigues, L; Wang, H, 2017) |
| " The moderate hyperglycaemia seen in prediabetes can be treated using a combination of metformin and lifestyle interventions (low-calorie diets and exercising)." | 4.12 | Ameliorative Effects of a Rhenium (V) Compound with Uracil-Derived Ligand Markers Associated with Hyperglycaemia-Induced Renal Dysfunction in Diet-Induced Prediabetic Rats. ( Akinnuga, AM; Booysen, IN; Ismail, MB; Khathi, A; Khumalo, B; Ngubane, P; Sibiya, NH; Siboto, A, 2022) |
| "Uracil fed as 3% of the diet to rats produces urinary calculi and consequent proliferative lesions of the bladder epithelium, including papillomatosis." | 3.67 | Uracil-induced calculi and proliferative lesions of the mouse urinary bladder. ( Cohen, SM; Masui, T; Sakata, T; St John, M, 1988) |
| " Dose-response curves following single intraperitoneal injections of purified CYN (at 0, 16, 32, 64 and 128 μg CYN/kg body weight) were created in 10-week-old male BALB/C mice (n = 4)." | 1.48 | Renal tubular damage caused by cylindrospermopsin (cyanotoxin) in mice. ( Magalhães, VF; Moraes, ACN, 2018) |
| "Alogliptin treatment tended to decrease UAlbCR (99." | 1.42 | Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes. ( Hayakawa, M; Kobori, H; Mizushige, T; Nishijima, Y; Nishiyama, A; Sakata, K; Yano, Y, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Siboto, A | 2 |
| Akinnuga, AM | 2 |
| Khumalo, B | 2 |
| Ismail, MB | 2 |
| Booysen, IN | 2 |
| Sibiya, NH | 2 |
| Ngubane, P | 2 |
| Khathi, A | 2 |
| Moraes, ACN | 1 |
| Magalhães, VF | 1 |
| Watanabe, Y | 1 |
| Mizushige, T | 1 |
| Kobori, H | 1 |
| Nishijima, Y | 1 |
| Yano, Y | 1 |
| Sakata, K | 1 |
| Hayakawa, M | 1 |
| Nishiyama, A | 1 |
| Khatri, A | 1 |
| Dutta, S | 1 |
| Marbury, TC | 1 |
| Preston, RA | 1 |
| Rodrigues, L | 1 |
| Wang, H | 1 |
| Awni, WM | 1 |
| Menon, RM | 1 |
| Bruckschen, EG | 1 |
| Henze, F | 1 |
| Michael, G | 1 |
| Sakata, T | 1 |
| Masui, T | 1 |
| St John, M | 1 |
| Cohen, SM | 1 |
2 trials available for uracil and Kidney Diseases
| Article | Year |
|---|---|
Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combinat | 2017 |
[Clinical trials of urapidil. Review of human pharmacological studies with a summary of a multi-center study].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Electrophysiology; Femal | 1978 |
5 other studies available for uracil and Kidney Diseases
| Article | Year |
|---|---|
Ameliorative Effects of a Rhenium (V) Compound with Uracil-Derived Ligand Markers Associated with Hyperglycaemia-Induced Renal Dysfunction in Diet-Induced Prediabetic Rats.
Topics: Animals; Diabetes Mellitus, Type 2; Diet; Glomerular Filtration Rate; Hyperglycemia; Kidney; Kidney | 2022 |
Ameliorative Effects of a Rhenium (V) Compound with Uracil-Derived Ligand Markers Associated with Hyperglycaemia-Induced Renal Dysfunction in Diet-Induced Prediabetic Rats.
Topics: Animals; Diabetes Mellitus, Type 2; Diet; Glomerular Filtration Rate; Hyperglycemia; Kidney; Kidney | 2022 |
Ameliorative Effects of a Rhenium (V) Compound with Uracil-Derived Ligand Markers Associated with Hyperglycaemia-Induced Renal Dysfunction in Diet-Induced Prediabetic Rats.
Topics: Animals; Diabetes Mellitus, Type 2; Diet; Glomerular Filtration Rate; Hyperglycemia; Kidney; Kidney | 2022 |
Ameliorative Effects of a Rhenium (V) Compound with Uracil-Derived Ligand Markers Associated with Hyperglycaemia-Induced Renal Dysfunction in Diet-Induced Prediabetic Rats.
Topics: Animals; Diabetes Mellitus, Type 2; Diet; Glomerular Filtration Rate; Hyperglycemia; Kidney; Kidney | 2022 |
Renal tubular damage caused by cylindrospermopsin (cyanotoxin) in mice.
Topics: Alkaloids; Animals; Bacterial Toxins; Biomarkers; Collagen; Cyanobacteria Toxins; Dose-Response Rela | 2018 |
[Renal Cancer after Spontaneous Rupture Successfully Treated with Low-Dose Oral UFT - A Case Report].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Kidney Diseases; Kidney N | 2018 |
Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes.
Topics: Aged; Albumins; Angiotensinogen; Biomarkers; Creatinine; Diabetes Mellitus, Type 2; Female; Humans; | 2015 |
Uracil-induced calculi and proliferative lesions of the mouse urinary bladder.
Topics: Animals; Cell Division; DNA; Dose-Response Relationship, Drug; Female; Hydronephrosis; Kidney Diseas | 1988 |